Trial Profile
An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus [T1DM]
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors ViaCyte Inc
- 03 Apr 2023 Status changed from active, no longer recruiting to discontinued due to Insufficient functional product engraftment.
- 18 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2021 Results presented in a ViaCyte Media Release.